Sunmax Biotechnology Co., Ltd.
4728
Rank in Stocks
#10815
Established in Tainan City, Taiwan, in 2001, Sunmax Biotechnology Co., Ltd.... Established in Tainan City, Taiwan, in 2001, Sunmax Biotechnology Co., Ltd. functions as a biomedical enterprise. The company specializes in the development, manufacturing, and commercialization of collagen-based medical devices across Taiwan and mainland China. Its diverse product line encompasses Porcogen, a sterile, purified collagen solution valuable for medical device applications, tissue engineering, and research. Sunmax also supplies various dermal fillers, including the Sunmax collagen implant series (I-Plus, I) and FACIALGAIN collagen implants (with and without lidocaine), engineered for correcting facial aesthetic concerns such as wrinkles. For dental procedures, they provide specialized collagen-based solutions like Sunmax collagen dental bone grafts, membranes, and granules, used for augmenting or reconstructing the alveolar ridge, extraction sockets, and in periodontics. Additionally, the Sunmax collagen bone graft matrix serves as a bone void filler that naturally resorbs and facilitates new bone formation during recovery. The company's offerings extend to skincare products, such as Sunmax 12 jiao didi spray, Sunmax 11 collagen moisturizing cream, and a general collagen skincare line, all designed for post-dermal filler treatment aftercare.
Share Price
$11.83
Last synced: 2026-11-10
Market Cap
$644.19M
Change (1 day)
-1.02%
Change (1 year)
-7.78%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sunmax Biotechnology Co., Ltd. (4728)
Category
Healthcare
Operating Margin for Sunmax Biotechnology Co., Ltd. (4728)
Operating Margin as of November 2026 TTM: 57.94%
According to Sunmax Biotechnology Co., Ltd.'s latest financial reports, its current operating margin (TTM) is 57.94%. At the end of 2025 the company had an operating margin of 49.27%.
Operating Margin history for Sunmax Biotechnology Co., Ltd. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 57.94% | 17.60% |
| 2025 | 49.27% | -3.37% |
| 2024 | 50.99% | -3.76% |
| 2023 | 52.98% | -4.63% |
| 2022 | 55.55% | 58.67% |
| 2021 | 35.01% | -13.51% |
| 2020 | 40.48% | 37.08% |
| 2019 | 29.53% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.33% |
US
|
|
| -149.01% | -102.57% |
US
|
|
| 25.57% | -99.56% |
AU
|
|
| 31.23% | -99.46% |
BE
|
|
| 29.35% | -99.49% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Sunmax Biotechnology Co., Ltd.'s operating margin
What is Sunmax Biotechnology Co., Ltd.'s operating margin?
Sunmax Biotechnology Co., Ltd.'s operating margin is 57.94%, as of Nov 2026.
What was Sunmax Biotechnology Co., Ltd.'s operating margin in 2025?
In 2025, Sunmax Biotechnology Co., Ltd.'s operating margin was 49.27%, compared with 50.99% in 2024.
How has Sunmax Biotechnology Co., Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Sunmax Biotechnology Co., Ltd.'s operating margin was highest in 2022 (55.55%) and lowest in 2021 (35.01%).
How does Sunmax Biotechnology Co., Ltd.'s operating margin compare with similar companies?
Sunmax Biotechnology Co., Ltd.'s operating margin (57.94%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.